Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

IL-2 selective agonists and antagonists

A technology of IL-2 and IL-2R, applied in the fields of pharmacology and immunology, can solve problems such as not including, not describing the potential of low toxicity mutant proteins

Inactive Publication Date: 2012-12-12
AICURIS GMBH & CO KG
View PDF15 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although these references refer to "selective agonist" IL-2 muteins, they do not describe their potential as hypotoxic muteins, but rather as potential antagonists of endogenous IL-2
[0019] EP 0267 795 A2 (Zurawski et al.) discloses various mouse IL-2 muteins throughout the sequence, including some containing deletions and / or substitutions in the first 30 N-terminal amino acid residues that are biologically active but did not include, discuss or suggest the amino acid substitutions disclosed herein at the same mouse IL-2 residue

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • IL-2 selective agonists and antagonists
  • IL-2 selective agonists and antagonists
  • IL-2 selective agonists and antagonists

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0101] Example 1. Production of muteins in E. coli

[0102] Essentially as described in Kunkel TA, Roberts JD and Zakour RA, "Rapid and efficient site-specific mutagenesis without phenotypic selection", (1987), Methods Enzymol 154:367-382, using Primers for the desired mutated codons were subjected to site-directed mutagenesis to generate muteins. Briefly, human IL-2 cDNA containing restriction enzyme sites Bam HI and Xba I was subcloned into the M13 phage vector M13 mp19 (New England Biolabs, Beverly, MA) using the same sites. Wild-type IL-2 cDNA was obtained using polymerase chain reaction ("PCR") from a cDNA library generated from human cells induced with 12-myristate 13-acetate flubolate (10 ng / ml) for 24 hours. mRNA isolated from peripheral blood lymphocytes. The PCR primer used is the 5' end of the IL-2 open reading frame,

[0103] 5'-CCT CAA CTC CTG AAT TCA TGT ACA GGA TGC-3' (SEQ ID NO: 3);

[0104] and the 3' end of the IL-2 open reading frame,

[0105] 5'-GGA AG...

Embodiment 2

[0113] Example 2. Extraction and purification of IL-2 mutein from Escherichia coli

[0114] After 3 hours of induction, cells were collected by centrifugation at 10,000 xg. Recombinant IL-2 muteins were first refolded and purified by dispersing cells in 10 volumes (vol / wet weight) of sucrose / Tris / EDTA buffer (0.375M sucrose, 10 mM Tris / HCl pH 8.0, 1 mM EDTA). The dispersed cells were sonicated 3 times at 300W with 30 second rest intervals on an ice bath using a Missonix XL2020 model sonicator equipped with a 1 inch standard probe. The sonicated material was then centrifuged at 17,000 xg, 4°C for 20 minutes. The pellet, which should be white at this point, was washed by resuspending in sucrose / Tris / EDTA buffer and centrifuging once, resuspending in Tris / EDTA buffer (50 mM Tris / HCL pH 8.0, 1 mM EDTA) and centrifuging twice. times, finally resuspended in 10 volumes of 0.1M Tris / HCL, pH 8.0 buffer (at which time a sample was taken for gel analysis) and centrifuged at 17,000 xg f...

Embodiment 3

[0116] Example 3. T cell proliferation analysis

[0117] Peripheral blood mononuclear cells (PBMC) were isolated from approximately 100 mL of normal human blood (Irwin Memorial Blood Bank, San Francisco, CA) in cold Dulbecco's phosphate-buffered saline (Ca 2+ and Mg 2+ free; DPBS) at a 1:2 dilution. Ficoll-Paque (Pharmacia) was placed in the lower layer, and the samples were centrifuged to separate PBMCs, followed by extensive washing in cold DPBS. PHA blasts (activated T cells) were generated by the following method: 1×10 6 Cells / ml density Cells were resuspended in RPMI 1640 containing 10% fetal bovine serum (Hyclone) supplemented with 1% (w / v) of the following: L-glutamine, non-essential amino acids, sodium pyruvate and Antibiotic-antimycotic (RPMI medium). Phytohemagglutinin (PHA-P; Sigma) was added at a final concentration of 10 μg / mL, and the cells were incubated at 37°C, 5% CO 2 Cultured for 3 days. Cells were harvested and washed twice in DPBS, resuspended in RPM...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention is directed to a polypeptide comprising a human IL-2 mutein numbered in accordance with wild-type IL-2 wherein said human IL-2 is substituted at at least one of positions 20, 88 or 126, whereby said mutein preferentially activates T cells over NK cells. D20H and I, N88G, I, and R, in particular have a relative T cell-differential activity much greater than native IL-2, with predicted associated reduced in vivo toxicity. The invention also includes polynucleotides coding for the muteins of the invention, vectors containing the polynucleotides, transformed host cells, pharmaceutical compositions comprising the muteins, and therapeutic methods of treatment.

Description

[0001] This application is a Chinese patent application (national application number is No.99808650.9, international application number is PCT / US99 / 10643) divisional application. [0002] Cross References to Related Applications [0003] This patent is a continuation-in-part of US Serial No. 09 / 080,080, filed May 15,1998. 1. Technical field [0004] The present invention relates generally to the fields of pharmacology and immunology. More specifically, the present invention relates to novel compositions that selectively activate T cells (PHA-blasts) while reducing the activation of natural killer cells ("NK"). The novel compositions include variants of a family of cytokines, particularly human interleukin-2 ("IL-2"). 2. Background technology [0005] Interleukin 2 (IL-2) is a potent immunostimulant that activates different cells of the immune system, including T cells, B cells and monocytes. IL-2 is also a potent and critical T cell growth factor. With these activities...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12Q1/02G01N33/50A61K38/00A61K38/20A61P35/00A61P37/00C07K14/55C12N15/09C12N15/26G01N33/15
CPCC07K14/55A61K38/00A61P31/00A61P31/18A61P35/00A61P37/00A61P37/04
Inventor A·B·沙纳菲尔特J·M·格雷维G·杰斯莫克K·J·伦巴赫G·D·韦策尔
Owner AICURIS GMBH & CO KG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com